Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Staggering Spots to Stargaze All over the Planet - 2'War is not over': Detailed diagrams of prisons found in cells of Oct. 7 terrorists
- 3Savvy Cleaning: The 6 Robot Vacuums of 2024
- 4'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- 5How did life begin on Earth? New experiments support 'RNA world' hypothesis
- Agricultural drones are taking off globally, saving farmers time and money
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Ariana Grande says Eternal Sunshine 2026 tour will be her last for a 'long, long time': 'One last hurrah'
- World's oldest known tortoise still very much alive despite rumor to the contrary
- Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- As world leaders enter climate talks, people in poverty have the most at stake
- New method spots signs of Earth's primordial life in ancient rocks
- Miss 'Stranger Things' already? Here's how you can get your Upside Down fix in 2026 with spinoffs, games and more
- The Appearance of Experience: Embracing the Reduced Portage Horse
